{
    "ticker": "TNONW",
    "name": "Titan Pharmaceuticals, Inc.",
    "description": "Titan Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing innovative therapeutics for the treatment of chronic diseases and serious medical conditions. Founded in 1992, Titan is best known for its proprietary drug delivery technology, which enables the long-term controlled release of medications through subdermal implants. This unique delivery system is designed to improve patient compliance and enhance therapeutic outcomes. Titan's lead product, Probuphine, a subdermal implant for the treatment of opioid addiction, exemplifies the company's commitment to addressing significant unmet medical needs. The company is also exploring other therapeutic opportunities, leveraging its technology platform to develop products for various indications, including pain management and hormonal therapies. With a strong emphasis on research and development, Titan Pharmaceuticals aims to revolutionize treatment paradigms in addiction and other chronic diseases, providing patients with safer and more effective therapeutic options. The company's mission underscores its dedication to improving the quality of life for patients while contributing to the advancement of medical science.",
    "industry": [
        "Biotechnology",
        "Pharmaceuticals"
    ],
    "headquarters": "San Francisco, California, USA",
    "founded": "1992",
    "website": "https://www.titanpharm.com",
    "ceo": "Marc Rubin",
    "social_media": {
        "twitter": "https://twitter.com/TitanPharma",
        "linkedin": "https://www.linkedin.com/company/titan-pharmaceuticals/"
    },
    "investor_relations": "https://www.titanpharm.com/investor-relations/",
    "key_executives": [
        {
            "name": "Marc Rubin",
            "position": "CEO"
        },
        {
            "name": "Kurt E. Gunter",
            "position": "CFO"
        }
    ],
    "product_categories": [
        {
            "category": "Pharmaceutical Products",
            "products": [
                "Probuphine"
            ]
        },
        {
            "category": "Drug Delivery Systems",
            "products": [
                "Subdermal Implants"
            ]
        }
    ],
    "seo": {
        "meta_title": "Titan Pharmaceuticals, Inc. | Innovative Therapeutics for Chronic Diseases",
        "meta_description": "Explore Titan Pharmaceuticals, Inc., a leader in developing innovative drug delivery systems and therapeutics for chronic diseases. Learn about our mission and products.",
        "keywords": [
            "Titan Pharmaceuticals",
            "Probuphine",
            "Biotechnology",
            "Chronic Diseases",
            "Opioid Addiction"
        ]
    },
    "faq": [
        {
            "question": "What is Titan Pharmaceuticals known for?",
            "answer": "Titan Pharmaceuticals is known for its innovative drug delivery systems and its lead product, Probuphine, for opioid addiction treatment."
        },
        {
            "question": "Who is the CEO of Titan Pharmaceuticals?",
            "answer": "Marc Rubin is the CEO of Titan Pharmaceuticals, Inc."
        },
        {
            "question": "Where is Titan Pharmaceuticals headquartered?",
            "answer": "Titan Pharmaceuticals is headquartered in San Francisco, California, USA."
        },
        {
            "question": "What are Titan's main products?",
            "answer": "Titan's main product is Probuphine, a subdermal implant for the treatment of opioid addiction."
        },
        {
            "question": "When was Titan Pharmaceuticals founded?",
            "answer": "Titan Pharmaceuticals was founded in 1992."
        }
    ],
    "competitors": [
        "NVO",
        "PFE",
        "ABBV",
        "GILD"
    ],
    "related_stocks": [
        "JNJ",
        "MRNA",
        "AMGN",
        "REGN"
    ]
}